Fosamax and Osteonecrosis of the Jaw: Examining the Evidence for Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Occupational Risk Assessment

The legacy context of general health and science information has long served as a foundation for public understanding of medication risks and benefits. Within this framework, discussions of pharmaceutical safety typically emphasize broad population-level outcomes and established clinical guidelines. As we pivot toward a more focused occupational exposure concern, it becomes necessary to narrow the lens from general health advisories to specific, high-stakes scenarios encountered in professional settings. In the domain of mass production, where workers may handle or be exposed to pharmaceutical compounds during manufacturing, packaging, or quality control, the transition from general health information to occupational risk assessment is critical. This shift requires examining how routine exposure in a production environment differs from patient-level therapeutic use. The bridge concept here moves from the abstract, population-based health warnings about medications like Fosamax to the concrete, repeated exposure pathways that production personnel might face. Such occupational contexts demand a distinct evaluation of risk, separate from clinical prescribing guidelines, as the nature, duration, and intensity of exposure can vary significantly. This transition sets the stage for a more targeted inquiry into whether and how workplace exposure to such compounds may correlate with adverse outcomes, without yet making specific mechanistic claims.

Bridging to Clinical Evidence: Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The question of whether Fosamax causes ONJ requires careful examination of clinical evidence, pharmacological mechanisms, and risk factors. Clinical evidence from FDA-approved labeling indicates that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The labeling explicitly states: "Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including FOSAMAX" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This association is further supported by labeling for Fosamax Plus D, which notes that known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Clinical Considerations

Mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but research provides insights. A multiscale characterization of jawbone offers comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Bisphosphonates like Fosamax inhibit osteoclast-mediated bone resorption, which can suppress normal bone turnover. In the jaw, which has high bone turnover rates and is subject to microtrauma from chewing and dental procedures, this suppression may impair healing and lead to necrotic bone exposure. The labeling notes that the time to onset of symptoms varied from one day to several months after starting the drug, and that most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), suggesting that ONJ is a rare adverse event that may not be statistically distinguishable from background incidence in controlled trials.

Adequacy of Warnings and Causation Assessment

Regarding adequacy of warnings, the FDA-approved labeling for Fosamax includes a dedicated section (5.4) on Osteonecrosis of the Jaw, which describes the condition, associated risk factors, and clinical management recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The labeling advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This warning is considered adequate for informing prescribers and patients of the potential risk, though individual cases may still occur despite adherence to precautions. Causation considerations for affected patients involve evaluating the timeline between exposure and documented harm. The labeling reports that the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability complicates establishing a direct causal link in individual cases, as ONJ can also occur spontaneously or due to other risk factors. The presence of known risk factors, such as dental procedures or cancer therapy, may confound the association. However, the recurrence of symptoms upon rechallenge with bisphosphonates provides evidence of a drug-related effect in some patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients who develop ONJ while on Fosamax, a thorough evaluation of risk factors and temporal relationship is necessary to assess causation.

Summary and Risk Context

In summary, the evidence supports that Fosamax is associated with an increased risk of ONJ, particularly in patients with additional risk factors such as invasive dental procedures, cancer, or concomitant therapies. The risk may increase with longer duration of bisphosphonate use. While the FDA labeling provides warnings and management recommendations, individual causation requires careful clinical assessment. Patients and healthcare providers should weigh the benefits of Fosamax for osteoporosis prevention and treatment against the rare but serious risk of ONJ.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does Fosamax cause osteonecrosis of the jaw?

Fosamax (alendronate) is associated with an increased risk of osteonecrosis of the jaw (ONJ), as reported in FDA-approved labeling. The labeling states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, in placebo-controlled trials, the incidence was similar between Fosamax and placebo groups, indicating it is a rare event.

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

How long does it take for ONJ to develop after starting Fosamax?

The time to onset of symptoms varies from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief after stopping the medication.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.